An Update on the Diagnosis and Treatment of Parkinson Disease

Overview

Journal CMAJ

Date 2016 May 26

PMID 27221269

Citations 155

Authors

Philippe Rizek

Niraj Kumar

Mandar S Jog

Affiliations

Soon will be listed here.

Citing Articles

Selenoproteins: Zoom-In to Their Metal-Binding Properties in Neurodegenerative Diseases.

Duta C, Muscurel C, Dogaru C, Stoian I Int J Mol Sci. 2025; 26(3).

PMID: 39941073 PMC: 11818150. DOI: 10.3390/ijms26031305.

Wild-Type Strains Respond Differentially to Rotenone Exposure.

Chaudhary S, Iyer S, Tare M MicroPubl Biol. 2025; 2025.

PMID: 39936041 PMC: 11811766. DOI: 10.17912/micropub.biology.001380.

Trends and Disparities in Parkinson's Disease Mortality in the United States with Predictions Using Machine Learning.

Weresh H, Hermann K, Al-Salahat A, Noor A, Billion T, Chen Y NeuroSci. 2025; 6(1.

PMID: 39846565 PMC: 11755521. DOI: 10.3390/neurosci6010006.

Pranayama (yogic breathing practices) in Parkinson's disease: protocol for a scoping review of literature.

Rao P, Agarwal D, Rohatgi S, Chaturvedi S BMJ Open. 2025; 14(12):e092315.

PMID: 39806643 PMC: 11667350. DOI: 10.1136/bmjopen-2024-092315.

Effectiveness of robot-assisted training in adults with Parkinson's disease: a systematic review and meta-analysis.

Lazzarini S, Mosconi B, Cordani C, Arienti C, Cecchi F J Neurol. 2024; 272(1):22.

PMID: 39666104 DOI: 10.1007/s00415-024-12798-z.

References

Rolinski M, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Talbot K, Ben-Shlomo Y . REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013; 85(5):560-6. PMC: 3995329. DOI: 10.1136/jnnp-2013-306104. View

Chase T, Mouradian M, Engber T . Motor response complications and the function of striatal efferent systems. Neurology. 1993; 43(12 Suppl 6):S23-7. View

Rosenblum S, Samuel M, Zlotnik S, Erikh I, Schlesinger I . Handwriting as an objective tool for Parkinson's disease diagnosis. J Neurol. 2013; 260(9):2357-61. DOI: 10.1007/s00415-013-6996-x. View

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

Schrag A, Ben-Shlomo Y, Brown R, Marsden C, Quinn N . Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality. Mov Disord. 1998; 13(6):885-94. DOI: 10.1002/mds.870130605. View

Vingerhoets F, Schulzer M, Calne D, Snow B . Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol. 1997; 41(1):58-64. DOI: 10.1002/ana.410410111. View

Solla P, Fasano A, Cannas A, Mulas C, Marrosu M, Lang A . Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. Parkinsonism Relat Disord. 2015; 21(8):968-71. DOI: 10.1016/j.parkreldis.2015.05.018. View

Luk K, Lee V . Modeling Lewy pathology propagation in Parkinson's disease. Parkinsonism Relat Disord. 2013; 20 Suppl 1:S85-7. PMC: 4034060. DOI: 10.1016/S1353-8020(13)70022-1. View

Baumann C . Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S90-2. DOI: 10.1016/S1353-8020(11)70029-3. View

10.

Mahler L, Ramig L, Fox C . Evidence-based treatment of voice and speech disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg. 2015; 23(3):209-15. DOI: 10.1097/MOO.0000000000000151. View

11.

Schrag A, Quinn N . Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000; 123 ( Pt 11):2297-305. DOI: 10.1093/brain/123.11.2297. View

12.

Follett K, Weaver F, Stern M, Hur K, Harris C, Luo P . Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010; 362(22):2077-91. DOI: 10.1056/NEJMoa0907083. View

13.

Hernan M, Takkouche B, Caamano-Isorna F, Gestal-Otero J . A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002; 52(3):276-84. DOI: 10.1002/ana.10277. View

14.

Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W . Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66(7):968-75. DOI: 10.1212/01.wnl.0000215437.80053.d0. View

15.

Kieburtz K, Wunderle K . Parkinson's disease: evidence for environmental risk factors. Mov Disord. 2012; 28(1):8-13. DOI: 10.1002/mds.25150. View

16.

Marras C, Lang A, Krahn M, Tomlinson G, Naglie G . Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord. 2004; 19(1):22-8. DOI: 10.1002/mds.10642. View

17.

Covy J, Giasson B . α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology. 2011; 32(5):622-9. PMC: 3134594. DOI: 10.1016/j.neuro.2011.01.003. View

18.

Burkhard P . Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord. 2013; 20 Suppl 1:S108-12. DOI: 10.1016/S1353-8020(13)70027-0. View

19.

Castro Jimenez M, Vingerhoets F . Tremor revisited: treatment of PD tremor. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S93-5. DOI: 10.1016/S1353-8020(11)70030-X. View

20.

Ossig C, Reichmann H . Treatment of Parkinson's disease in the advanced stage. J Neural Transm (Vienna). 2013; 120(4):523-9. PMC: 3611036. DOI: 10.1007/s00702-013-1008-y. View